We are live on ! Find out more
ARRY icon

Array Biopharma
ARRY

Delisted

ARRY was delisted on the 29th of July, 2019.

112 hedge funds and large institutions have $432M invested in Array Biopharma in 2014 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 35 increasing their positions, 33 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

27% more capital inflows, than outflows

Capital inflows: $22.8M | Capital outflows: $18M

6% more repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 33

0.88% more ownership

Funds ownership: 70.86% → 71.74% (+0.88%)

13% less funds holding

Funds holding: 129 → 112 (-17)

28% less call options, than puts

Call options by funds: $1.81M | Put options by funds: $2.53M

40% less funds holding in top 10

Funds holding in top 10: 5 → 3 (-2)

61% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 28

Holders
112
Holders Change
-17
Holders Change %
-13.18%
% of All Funds
3.24%
Holding in Top 10
3
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-40%
% of All Funds
0.09%
New
11
Increased
35
Reduced
33
Closed
28
Calls
$1.81​M
Puts
$2.53​M
Net Calls
-⁠$718​K
Net Calls Change
+$1.42​M

ARRY Hedge Fund Activity: Q3 2014 in Review

112 of the 3,454 institutional investors tracked by Wall St. Rank reported a position in Array Biopharma (ARRY) for Q3 2014, worth a combined $432M — down 21% from $545M a quarter earlier.

Sellers outnumbered buyers: 28 funds closed out of ARRY and 11 opened new positions — a net loss of 17 holders — while 33 trimmed existing stakes and 35 added.

The largest buyer was Point72 Asset Management, opening a new position worth an estimated $5.62M. The largest seller was BVF Inc, cutting an estimated $3.31M.

  • 112 institutional investors held Array Biopharma (ARRY) as of Q3 2014, down from 129 in Q2 2014.
  • Funds reported $432M of Array Biopharma stock for Q3 2014, down 21% quarter-over-quarter.
  • 11 funds opened new Array Biopharma positions in Q3 2014 and 28 closed out, a net change of -17 holders.
  • The largest Array Biopharma buyer in Q3 2014 was Point72 Asset Management, an estimated $5.62M added.
  • The largest Array Biopharma seller in Q3 2014 was BVF Inc, an estimated $3.31M sold.

Based on aggregated 13F filings for Q3 2014.